These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32019780)

  • 1. Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments.
    Xie YJ; Dougan M; Ingram JR; Pishesha N; Fang T; Momin N; Ploegh HL
    Cancer Immunol Res; 2020 Apr; 8(4):518-529. PubMed ID: 32019780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
    Hanssens H; Meeus F; De Vlaeminck Y; Lecocq Q; Puttemans J; Debie P; De Groof TWM; Goyvaerts C; De Veirman K; Breckpot K; Devoogdt N
    Front Immunol; 2024; 15():1389018. PubMed ID: 38720898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
    Lu Q; Li H; Wu Z; Zhu Z; Zhang Z; Yang D; Tong A
    J Nanobiotechnology; 2024 May; 22(1):279. PubMed ID: 38783333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment.
    Qiu Y; Liao P; Wang H; Chen J; Hu Y; Hu R; Zhang H; Li Z; Cao M; Yang Y; Li M; Xie X; Li Y
    Int J Biol Sci; 2023; 19(15):4948-4966. PubMed ID: 37781520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
    Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
    Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.
    Xie YJ; Dougan M; Jailkhani N; Ingram J; Fang T; Kummer L; Momin N; Pishesha N; Rickelt S; Hynes RO; Ploegh H
    Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7624-7631. PubMed ID: 30936321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
    Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
    Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
    Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
    Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.
    Blobner J; Dengler L; Eberle C; Herold JJ; Xu T; Beck A; Mühlbauer A; Müller KJ; Teske N; Karschnia P; van den Heuvel D; Schallerer F; Ishikawa-Ankerhold H; Thon N; Tonn JC; Subklewe M; Kobold S; Harter PN; Buchholz VR; von Baumgarten L
    Cancer Immunol Immunother; 2024 Oct; 73(12):255. PubMed ID: 39358663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs.
    Rahbarizadeh F; Ahmadvand D; Moghimi SM
    Adv Drug Deliv Rev; 2019 Feb; 141():41-46. PubMed ID: 31004624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies.
    Zhang YC; Li XY; Deng Q; Ge YJ; Yi RR; Wang HJ; Wang JT; Zhou H; Kong XF; Liu RJ; Zhang YT; Li XP; He XW; Zhu HY
    Theranostics; 2024; 14(16):6249-6267. PubMed ID: 39431011
    [No Abstract]   [Full Text] [Related]  

  • 16. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
    Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
    Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
    Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
    Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
    Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.
    Hanssens H; Meeus F; Gesquiere EL; Puttemans J; De Vlaeminck Y; De Veirman K; Breckpot K; Devoogdt N
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.